Ambry Genetics, a wholly owned subsidiary of Tempus AI, announced that it has completed its one‑millionth RNA‑enabled hereditary cancer and rare disease diagnostic test. The milestone, reached on February 2 2026, marks the largest single‑company deployment of paired DNA/RNA testing in the industry and underscores the growing adoption of this technology across clinical laboratories.
The integrated RNA data improves diagnostic accuracy by identifying deep intronic pathogenic variants and reduces uncertain variant classifications by 6%. In a sample of 450,000 patients, 1 in 25 positive cases would have been missed without RNA, and the approach has a greater impact on variant classification in non‑White patients, helping to close equity gaps in genetic testing. The milestone demonstrates that Ambry’s platform can scale to meet increasing demand while delivering clinically actionable insights that were previously unattainable with DNA‑only testing.
Ambry’s growth has been a key driver of Tempus AI’s revenue expansion. The company’s revenues have grown at over 25% annually, and its operations generate meaningful EBITDA and cash flow. By adding one million RNA‑enabled tests, Ambry is expanding the data set that feeds Tempus’s AI algorithms, enabling more precise risk stratification and therapeutic recommendations. The milestone also aligns with the launch of ExomeReveal in 2024, which extends RNA testing into rare disease diagnostics and further broadens the company’s market reach.
Tom Schoenherr, CEO of Ambry Genetics, said the achievement “represents a million people who benefited from deeper genetic insights, allowing earlier risk identification and more informed clinical decisions.” Huma Q. Rana, a leading cancer genetics researcher, noted that the technology “clarifies diagnoses and changes management for patients who previously had uncertain results.”
The announcement was met with a muted market reaction as investors focused on broader market conditions. Analysts highlighted the milestone’s significance for Tempus’s AI strategy but noted that the company’s stock was already trading below key moving averages, tempering enthusiasm for the news.
Looking ahead, Ambry plans to continue expanding its RNA‑enabled test portfolio, targeting additional rare disease indications and integrating its data more deeply into Tempus’s AI platform. The company’s trajectory suggests sustained demand for RNA‑enhanced diagnostics, positioning it to capture a growing share of the precision medicine market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.